Trial Profile
A Phase I, Dose-Escalating Study to Assess the Safety, Tolerability, and Immunogenicity of Recombinant Anthrax Protective Antigen Vaccine (rPA) Administered in Two Intramuscular Doses to Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Oct 2009
Price :
$35
*
At a glance
- Drugs Recombinant protective antigen anthrax vaccine Altimmune (Primary) ; Anthrax vaccine
- Indications Anthrax
- Focus Adverse reactions
- 04 Nov 2005 New trial record.